Prize for TB low-cost point of care rapid diagnostic test Pierre Chirac Médecins Sans Frontières, Paris, France Campaign for Access to Essential Medicines.

Slides:



Advertisements
Similar presentations
THE CHALLENGES & OPORTUNITIES OF ACCESS TO MEDICINES IN AFRICA Dr Pascoal MOCUMBI, orig Mozambique,High Representative EDCTP ABRASCO/WFPHA.
Advertisements

Trade and Health National Assessment The World Health Organisations Diagnostic Tool on Trade and Health Presented by: Corinna Hawkes, Consultant
EUROPEAN COMMISSION Community health programmes: first results and future challenges for the EU regions Donata Meroni European Commission - DG Health and.
Mandate and Terms of Reference of the CEWG. The Presentation Background Mandate from the Resolution Points requiring clarity Resolution WHA63.28.
The de-linkage of the cost of research and development and the price of health products Michelle Childs Director Policy Advocacy.
Consultative expert working group - proposals Barcelona
WIPO Conference on Building Partnerships for Mobilizing Resources for Development Thematic Session 2 Science, Technology and Innovation for Development.
DEVELOPING COUNTRIES AND IP: ACCESS TO HEALTH CARE EDUCATION MATERIALS Karen A. LeCuyer, Ph.D. University of Connecticut School of Law 30 May 2007.
European R&D Support Programme ACCESSING EUROPEAN FUNDING FOR RESEARCH AND DEVELOPMENT.
INTERNATIONAL CONFERENCE ON GENDER EQUITY IN SPORTS FOR SOCIAL CHANGE
Post Research Benefits Mandika Wijeyaratne MS, MD, FRCS Dept. of Surgery, Colombo.
Global Consultation on the Implementation of the Xpert MTB/RIF system for rapid diagnosis of TB and MDR-TB M. Akhalaia, MD, Microbiologist, Reference.
Improving diagnosis TB laboratory strengthening.
Biomedical Engineering Initiative: Creating the next generation of healthcare innovators in Africa Muhammad H. Zaman Director, LEED, Boston University.
Broader Impacts: Meaningful Links between Research and Societal Benefits October 23, 2014 Martin Storksdieck I Center for Research on Lifelong STEM Learning.
Washington D.C., USA, July 2012www.aids2012.org The value of universal TB screening with GeneXpert MTB/RIF in pre-ART patients in Harare L. Mupfumi.
Advocacy for TB POC Diagnostic Javid Syed TB/HIV 15th Core Group Meeting Nov 3-4, Geneva.
Health Professional Students AIDS Advocacy Network Treat the People: Access to Essential AIDS Medications A Primer for Health Professional Students.
Game Changers Radicalization of ART tools and delivery New ways to manage IP: aggressive use of TRIPS flex and effective patent pool Financial transaction.
ARC Special Research Initiative for a Science of Learning Research Centre 24 April 2015 Professor Marian Simms Executive Director, SBE, ARC.
OIC-SHPA & Vaccines Need Assessment in OIC Member Countries
Andrew Gray March 10, Poverty Basic nutrition and clean water Shelter Education Basic medical care (public health) Lack of access.
IGWG process Gaudenz Silberschmidt, Switzerland Public Health, Innovation and Intellectual Property Global strategy and Plan of Action Dr Gaudenz Silberschmidt,
Innovation Policy, Environment and Growth: Basic Comments Keith Maskus University of Colorado at Boulder Prepared for CIES Workshop Graduate Institute,
Intellectual Property and Access to Affordable Medicines: TRIPS Plus
WIPO’s Strategies on Intellectual Property and Economic Development WIPO’s Strategies on Intellectual Property and Economic Development United Nations.
A very short introduction to patents & access to medicines.
Innovation in TB control: what’s in it for the field? Peter C.F.M. Gondrie, MD, MPH Executive Director
Working across sectors Building collaborative eco-systems Lars Sundstrom SARTRE.
IPA- EDQM SYMPOSIUM 2007 REFERENCE STANDARD DEVELOPMENT -IP PERSPECTIVE A.R Gomes – Sr.Director, Quality Control Dr.Reddy’s Laboratories.
The Role Of Prizes For Low-cost Point-of-care Rapid Diagnostic Test And Better Drugs For Tuberculosis James Love, KEI MSF expert meeting on IGWG and R&D.
IPRs serving innovation BioVision April Bibliotheca Alexandrina Ahmed Abdel Latif International Centre for Trade and Sustainable Development.
Partnerships and collaboration Working together: good for business, good for research I work for business.gov.au but also thought it would be a good opportunity.
The Research and Development Goals of the Global Plan to Stop TB Marcos Espinal Executive Secretary.
Center for Global Health R&D Policy Assessment Presentation to the WHO CEWG 6 April 2011 Kimberly Manno Reott, Project Director.
Analysis of Global Fund Support for Health Systems Strengthening Emily Trautner Geneva, Switzerland October 1, 2010.
Global Patent Debate K.Ravi Srinivas May 12-13, 2011.
Technology Strategy Board Driving Innovation Participation in Framework Programme 7 Octavio Pernas, UK NCP for Health (Industry) 11 th April 2012.
Implementation of Thin Layer Agar for Mycobacterium culture in rural Kenya Médecins Sans Frontières.
State HIE Program Chris Muir Program Manager for Western/Mid-western States.
Sustainable Approaches to Opening Access to Medical Inventions James Love Wizards of OS Berlin 15 Sept 06.
Update of the Global Plan to Stop TB TB/HIV Working Group Meeting Geneva, November 2009 Christian Lienhardt.
Program Co-Development in CME: Where have we been? Where are we going? Workshop Facilitators: Dr. Craig Campbell Dr. Jamie Meuser September 21,
Treating MDR-TB A Challenge Throughout ECA Public Health Practice II.
April_2010 Partnering initiatives at country level Proposed partnering process to build a national stop tuberculosis (TB) partnership.
Health Organization The Challenges Facing Tuberculosis Control Blantyre Hospital, Malawi: TB Division, 3 patients per bed.
Campana Salud para el Desarrollo Barcelona – Diciembre 2008 Judit Rius Sanjuan Knowledge Ecology International (KEI) Perspectivas futuras en la OMS.
Philippe Duneton11 February 2009 Deputy Executive Secretary 5th Consultative Stakeholder Meeting UN Prequalification of Diagnostics, Medicines & Vaccines.
Donors, prize funds and patent pools. KEI & UNU- MERIT Maastricht Workshop on Medical Innovation Prizes January 28th-29th 2008 Michelle Childs, Head of.
Alexandra Heumber Médecins Sans Frontières Access to Essential Medicines Campaign DEBRIEFING WHA May 2006.
Strategic Dialogue on Coherence Between Multilateral, Regional and Bilateral Processes on Intellectual Property and a pro-Development Agenda on IPRs 20.
Preliminary classification of proposals by the CEWG Proposals for innovative financing: Discussing the work to-date of WHO’S Consultative Expert Working.
Exploring financing options NATIONAL TB CONTROL OF VIETNAM.
Industry’s Perspective on Industry-University Intellectual Property External Research Directors Network Industrial Research Institute, Inc. April 17, 2001.
Public health, innovation and intellectual property 1 |1 | The Global Strategy on Public Health, Innovation and Intellectual Property Technical Briefing.
11 Laboratory Quality Improvement for clinical HIV/AIDS Services in the Uniformed Forces Mwaibako, J, Shija, L; Haverkamp, G; van den Hombergh; Katebalila,
GLOBAL COOPERATION FOR IP AND DEVELOPMENT Esteban Burrone Head of Policy Medicines Patent Pool.
Paris Bruxelles MoscouRabat HIV financing and social health protection mechanisms Elements for analysis and propositions.
Access to medicines challenges in Europe: What is wrong and the way forward Presented by: Rohit Malpani Director of Policy & Analysis, Access Campaign.
Moving towards a Patent Pool? XVII International AIDS Conference Satellite Forum, MSF, KEI, OXFAM (Mexico, 5 August 2008) Jorge Bermudez Executive-Secretary,
Taxonomy of Strategies
Intellectual Property and Access to Affordable Medicines: TRIPS Plus
ACCESS TO QUALITY MEDICINES IN THE REGION-COUNTERFEITING PROBLEMS
Georgian Research & Development Foundation (GRDF)
Novel approaches to TB infection control in private general hospitals in Georgia T Gabunia1, I Khonelidze, N Solomonia, T Merabishvili, M Makharadze,
Key issues in DOTS implementation
Institutional Framework, Resources and Management
Decent work on plantations Sri Lanka’s TEA sector
TB epidemiological situation in Kyrgyzstan
Rural Partnerships between Small Farmers and Private Sector
Presentation transcript:

Prize for TB low-cost point of care rapid diagnostic test Pierre Chirac Médecins Sans Frontières, Paris, France Campaign for Access to Essential Medicines

Present TB diagnostic methods leave half of all patients undiagnosed ! sputum smear microscopy: sensitivity < 50%, especially not suitable for: –children –HIV positive patients –extra-pulmonary TB

Better diagnostic tools exist Improved sputum collection and microscopy methods Liquid and solid culture Colorimetric redox indicators IGRA’s Molecular techniques Still lacking sensitivity and specificity Expensive Not suitable for the most peripheral settings: requires highly trained staff and/or highly equipped lab- infrastructure

What do we need? More needs-driven research for new TB diagnostic tools, taking especially into account the situation at peripheral level

Rapid, low cost, point of Care –Differentiate between active and latent TB especially in high HIV prevalence areas –High sensitivity especially for smear negatives and EP TB –Cheap –Easy to handle –Fast (results within hours) –Not sputum based / Usable for children –Suitable for follow up –Detecting Rifampicin resistance –….

How to facilitate the development of POC: MSF + experts meeting on TB prize, Geneva - April 2008 « Developing simple, point-of-care tests soon requires innovative strategies, both financial and scientific » « The most fruitful way forward is to work with a combination of different antigens that would optimise the sensitivity and specificity of any test » « That would require actors who work now separately to join together to share the current status of their individual research, sum up these results and perform further tests together » « Protecting knowledge through patent monopoly stands in the way of this kind of innovative collaboration » Industry interested if prize is big enough

POC TB test : best candidate for a prize… The low-cost POC TB test is a perfect candidate for testing innovative R&D mechanisms and funding This would perfectly be in line with the « Global strategy and plan of action on public health, innovation and intellectual property » the WHA adopted in May 2008 at the end of the IGWG process : –« Explore and (…) promote a range of incentive schemes for research and development including addressing (…) the de- linkage of the costs of research and development and the price of health products, for example through the award of prizes (…) »

A promising proposal Prize Fund for Development of Low-Cost Rapid Diagnostic Test for Tuberculosis, sponsored by Bolivia and Barbados. Presented during the IGWG process and expected to be considered soon by WHO

Grand Prix Grand Prix of 100 million dollars for a TB test (every 7 years) feasible to manufacture for 1 $ feasible at POC in developing countries results in 3 hours sensitivity = X % specificity = Y % = needs first = innovation + Access

Sub-prizes Awards (1 to 10 millions) for Small technical challenges Best contributions (every 2 years) Incentives to collaboration and access to knowledge = cash flow on short term = rewards incremental advance = rewards collaboration and open access

Monopoly free “Intellectual Property Rights For Grand Prix” A licensing pool would be created for acquiring needed rights for the relevant patents and know-how for the diagnostic test—the TB licensing agency (TBLA). In order to claim the Grand Prix, the winner would have to grant licenses to all patent and know-how needed for competitive supply of the test, worldwide.” = no monopoly = competition for production

Public funding Government would contribute to the prize Participating high-income countries would be expected to contribute 90 percent of the funds Developing countries would be expected to contribute 10 percent = public responsibility = equity

Administration The prize would be placed in the WHO, but administered by a committee including several institutions and representatives of the interests of TB patients

Outstanding questions Medical and operational specification IP - rights Price Partners How much money to be allocated? Money coming from? When ? Who ?

Invitation Any proposal on specifications, please come back to us :

Thank you